ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ABCL AbCellera Biologics Inc

2.80
0.09 (3.32%)
21 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
AbCellera Biologics Inc NASDAQ:ABCL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.09 3.32% 2.80 2.77 2.84 2.88 2.6818 2.7163 2,030,831 05:00:00

AbCellera to Present at Upcoming Investor Conferences in December and January

21/11/2024 9:05pm

Business Wire


AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more AbCellera Biologics Charts.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:

  • Piper Sandler 36th Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time)
  • 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time)

Live audio webcasts of the presentation may be accessed through the link that will be posted on AbCellera's Investor Relations website. Replays of the webcast will be available through the same links following the presentations.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

Inquiries

Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

1 Year AbCellera Biologics Chart

1 Year AbCellera Biologics Chart

1 Month AbCellera Biologics Chart

1 Month AbCellera Biologics Chart

Your Recent History

Delayed Upgrade Clock